Barry Shuman is a patent agent in the firm’s Orange County office. He is a member of the IP Procurement and Portfolio Management practice group. Barry has extensive experience in preparing and prosecuting patent applications in the United States and international/foreign intellectual property offices. He has prosecuted patent applications in organic chemistry, biotechnology, biochemistry, drug/pharmaceuticals, immunology, molecular biology, protein purification, treatment of medical conditions/diseases, polymers, materials science, cosmetics, business methods, instrumentation, printers, medical devices, mechanical systems, semiconductor, and communication technologies. Barry also has experience in patentability, freedom to operate, infringement opinions, and inter partes review proceedings.
Prior to becoming a patent agent, Barry was a scientist for a biotechnology company, where he was the associate director of assay development. In this role, he was responsible for the development and validation of numerous immunoassays in a wide variety of formats. In addition, he was responsible for the development and validation of a reverse transcription-polymerase chain reaction (RT-PCR) kit product line. Barry was the principal investigator and sole author of a successfully funded small business innovation research (SBIR) grant that studied the use of a luciferase system in nucleic acid detection.
Barry's doctorate work spanned synthetic organic chemistry, protein chemistry, and molecular biology. He worked as a post-doctoral associate in multiple leading cancer research institutes.